Company profile

FibroBiologics, Inc. CIK 1958777

Ticker

FBLG (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

Houston, TX 77054

Fiscal year end

2025 (FY)

Market Data

$1.00

Change

-$0.03

Change %

-2.91%

Volume

500

FBLG · trading date Oct 13, 2026 · previous close $1.03 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials

Revenue

—

Net income

-$18.65M

Total assets

$9.62M

Total liabilities

$3.46M

Stockholders' equity

$6.16M

Cash & equivalents

$4.89M

Operating income

-$16.65M

Operating cash flow

-$16.39M

Capital expenditures

$262.0K

Fiscal year 2025, via 10-K filed 2026-02-24. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance

Operating margin

—

Net margin

—

Free cash flow

-$16.66M

Free cash flow margin

—

Liabilities / assets

36.0%

Equity / assets

64.0%

CapEx / revenue

—

Operating cash flow / net income

0.88×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History

Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity

2025 — -$18.65M $9.62M $3.46M $6.16M

2024 — -$11.16M $16.45M $13.71M $2.74M

2023 — -$16.49M $11.82M $10.57M $1.25M

2022 — -$5.12M $4.82M $8.82M -$4.00M

Company Details

SIC code

2834

State of incorporation

Active filer

Yes

Most recent SEC filing

Form 8-K

2026-09-18

Financials filed via

Form 10-K

filed 2026-02-24

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location

Houston, TX 77054

9350 KIRBY DRIVE

Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:58 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to Texas — Public Companies